Apr. 10 at 2:37 AM
$INVA
Innoviva, Inc. has the greatest future revenue growth potential in the Innoviva Specialty Therapeutics (IST) segment, specifically within hospital-based critical care and infectious disease treatments. The IST division is experiencing rapid growth, with net product sales rising by 77% in 2025 to
$172.1 million and projected to exceed
$150 million in U.S. sales in 2026.
Key Products in High-Need Areas:
GIAPREZA® (septic shock): Identified as a major growth driver due to high unmet medical need.
XACDURO® (bacterial pneumonia): Showing strong commercial momentum and international adoption, particularly in China.
ZEVTERA® (MRSA/ bloodstream infections): Expected to launch in the U.S. in mid-2025, offering significant potential in the antimicrobial market.
NUZOLVENCE (gonorrhea): FDA-approved in 2026, targeting a high-unmet-need infectious disease area.
